Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab

Divyanshu Dubey, Christopher A. Cano, Olaf Stuve

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the manage­ment of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical develop­ment in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS.

Original languageEnglish (US)
Pages (from-to)2405-2414
Number of pages10
JournalNeuropsychiatric Disease and Treatment
StatePublished - Sep 18 2015


  • Alemtuzumab
  • CD52
  • Idiopathic thrombocytopenic purpura
  • Monoclonal antibody
  • Multiple sclerosis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab'. Together they form a unique fingerprint.

Cite this